85 results about "Metformin hcl" patented technology

The invention discloses a metformin empagliflozin tablet composition and a preparation method thereof. The metformin empagliflozin tablet composition is prepared from the following raw materials: metformin hydrochloride, empagliflozin, corn starch, copovidone, colloidal silicon dioxide, magnesium stearate and a gastric-soluble film coating premix. According to the metformin empagliflozin composition and the preparation method thereof, empagliflozin is dispersed in part of auxiliary materials, then mixing granulation is carried out through a wet granulator, empagliflozin and part of the auxiliary materials are premixed, and the particle size range of a metformin hydrochloride raw material is controlled, so that the problems of poor empagliflozin content uniformity and large inter-batch dissolution difference of the metformin empagliflozin composition prepared by a traditional process are solved; by controlling the mesh number of the wet granulation screen, the problems that materials adhere to the screen, discharging is difficult, and production efficiency is low in the wet granulation process are solved; compared with a fluidized bed production process, the equipment cost is low, the operation is simpler, and the production efficiency is higher; the pharmaceutical composition prepared by the preparation method disclosed by the invention is uniform in component mixing, simple to prepare, controllable in quality and consistent in in-vitro dissolution with an original preparation.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a saxagliptin metformin sustained release tablet and a preparation method thereof. The saxagliptin and metformin sustained release tablet comprises a saxagliptin pellet, a metformin hydrochloride pellet and a color coating, the saxagliptin pellet is prepared from the following raw materials: saxagliptin monohydrate, a silicon dioxide pellet core, hydroxypropyl methylcellulose, talcum powder and hydrochloric acid, the metformin hydrochloride pellet is prepared from the following raw materials: metformin hydrochloride, ethyl cellulose and triethyl citrate; the color coating comprises the following raw materials: a gastric-soluble film coating premix, hydrochloric acid and polyethylene glycol. The medicine is stable in quality, accurate in dosage and short in production time, and the quality is consistent with that of an original developed preparation.

The invention belongs to the technical field of medicines, and relates to a metformin hydrochloride-loaded PLGA (poly (lactic-co-glycolic acid)) nanoparticle material as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out first shear emulsification on a metformin hydrochloride aqueous solution and an organic solution containing a first emulsifier and PLGA (poly (lactic-co-glycolic acid)) to obtain a water-in-oil primary emulsion; carrying out second shear emulsification on the primary emulsion and an aqueous solution containing a second emulsifier to obtain a water-in-oil-in-water type crude emulsion; homogenizing and emulsifying the crude emulsion to obtain a W1 / O / W2 nano-emulsion; and removing the organic solvent from the nano-emulsion, centrifuging and drying to obtain the nano-emulsion. The preparation method disclosed by the invention not only has relatively high reproducibility for preparing the nano-particles, but also obviously reduces the average size of the obtained nano-particles, improves the bioavailability of the medicine, and simultaneously keeps the uniform dispersity and high biocompatibility of the nano-particles.

The invention belongs to the technical field of disease control and aquaculture, relates to specific therapeutic activity of metformin hydrochloride, and particularly relates to application of metformin hydrochloride in preparation of a medicine for resisting white spot syndrome. Experiments prove that the metformin hydrochloride can endow prawns with certain white spot syndrome virus resistance by inducing expression up-regulation of key members Ago2 and Dicer2 genes in a prawn RNAi (Ribonucleic Acid Interference) antiviral mechanism and antiviral effect factors AlfB1 and Dapper genes.

The invention belongs to the technical field of pharmaceutical preparations, relates to a metformin hydrochloride sustained-release tablet and a preparation method thereof, and aims to overcome the technical defects of insufficient release behavior regulation and control precision and poor stability of an existing metformin hydrochloride sustained-release preparation. The metformin hydrochloride sustained-release tablet disclosed by the invention takes metformin hydrochloride as an effective component, is matched with sustained-release materials including hydroxypropyl methyl cellulose, propylene carbonate, zein, a filling agent, an adhesive and a lubricating agent, and can be selectively matched with a gastric-soluble film coating material. According to the invention, the stable release of the medicine is realized, the initial burst release phenomenon is avoided, meanwhile, the stability of the preparation is remarkably improved, and the good slow release performance can still be maintained after long-term storage.

The application discloses a baicalin ternary co-amorphous drug and a preparation method and application thereof, and the amorphous substance can effectively improve the solubility and dissolution of puerarin and baicalin. The application mixes metformin hydrochloride, puerarin and baicalin according to a molar ratio of 1:1:1, and obtains the baicalin ternary co-amorphous drug through a ball milling method or a solvent-assisted milling method, the preparation method is green and efficient, the co-amorphous substance has high light stability and thermal stability, the solubility is increased by 1.7 times compared with that of a puerarin raw drug crystal, the solubility is increased by 46.8 times compared with that of a baicalin raw drug crystal, and the solubility is reduced by 14.8 times compared with that of a metformin hydrochloride raw drug crystal. The baicalin ternary co-amorphous drug has certain application prospects in liver protection, blood sugar reduction, treatment of damp-heat type colitis and cervical cancer.

The utility model discloses a metformin hydrochloride electrochemical analysis device which comprises a shell, and one side of the shell is provided with an electric sensor interface; the power supply unit is arranged in the shell and is used for generating polarization voltage; the silk-screen printing electrode electric sensor is electrically connected with the power supply unit and comprises a flexible electrode base body, a working electrode, a counter electrode, a reference electrode, an insulating layer, a wiring terminal and an electrode connecting wire, and the working electrode, the counter electrode, the reference electrode, the insulating layer, the wiring terminal and the electrode connecting wire are arranged on the flexible electrode base body; the surface of the working electrode is modified with an imprinted polymer with selective recognition on metformin hydrochloride; the signal processing unit is arranged in the shell and comprises a shunt resistor, an operational amplifier, a signal converter, a data storage chip and a microprocessor which are electrically connected in sequence; the display screen is electrically connected with the microprocessor and is used for displaying the converted concentration value; the method has the advantages that the metformin hydrochloride can be rapidly and accurately detected, and the use is relatively convenient.

The invention discloses a pharmaceutical composition for treating diabetes and a preparation method thereof.The pharmaceutical composition comprises a tablet core and a coating layer, the tablet core comprises metformin hydrochloride, linagliptin, an adhesive, a stabilizer, a diluent, a flow aid and a lubricant, the stabilizer is composed of sodium hydroxide and meglumine, and the diluent is composed of sodium hydroxide and meglumine. The pharmaceutical composition for treating diabetes mellitus has good dissolution and stability.

The utility model relates to a chemical system technical field especially relates to a kind of innocuous treatment system of metformin hydrochloride distillation residue. The method of ultrasonic digestion device and anaerobic reactor combination is used, pretreatment is carried out to distillation residue first, improves organic matter degradation rate, improves processing efficiency, then carries out anaerobic biochemical reaction to the pollutant after pretreatment, substantially digests the chemical oxygen demand in high concentration organic waste, makes pollutant reduction, reduces the final disposal cost of dangerous waste, and removal of harmful substances can be realized without good itch treatment. Meanwhile, the oxygen treatment step is saved, the technological process is simplified, the treatment time of distillation waste residue is shortened, the oxygen treatment equipment is reduced, and it is beneficial to cost saving.

The invention provides a dapagliflozin and metformin sustained-release tablet with stable dissolution and a preparation method of the dapagliflozin and metformin sustained-release tablet. Comprising the following steps: S1, respectively preparing metformin hydrochloride particles and dapagliflozin particles; s2, firstly tabletting and forming metformin hydrochloride particles, then adding dapagliflozin particles, and carrying out secondary tabletting, so as to obtain a dapagliflozin and metformin sustained-release tablet core; the mass ratio of the metformin hydrochloride particles to the dapagliflozin particles is (4-10): (0.1-1); and S3, coating the obtained tablet core with a coating solution to obtain the dapagliflozin and metformin sustained release tablet with stable dissolution. According to the dapagliflozin and metformin sustained release tablet, the RSD of the substance content of the metformin hydrochloride layer can reach 0.3%, the RSD of the substance content of the dapagliflozin layer can reach 0.1%, the sum of impurities of the metformin hydrochloride can not be detected, and the total impurity of the dapagliflozin can reach 0.06%. According to the invention, the process and the raw materials are optimally designed, so that the production link is simplified, and the problems of poor quality and the like caused by the distribution difference of the two effective components in the sustained release tablet are solved.

The invention provides a sitagliptin and metformin sustained-release pharmaceutical composition as well as a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer, the sustained-release tablet core comprises an active ingredient metformin hydrochloride and a sustained-release framework material hydroxypropyl methylcellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises an active component sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methylcellulose in the sustained release tablet core is 50: (24-27). The composition utilizes a double-layer structure to realize double-phase release of the medicine; the microcrystalline cellulose is removed, and the specific ratio of the active component to the framework material is limited, so that the moldability and ideal dissolution behavior of the preparation are ensured while the tablet weight is remarkably reduced to improve the swallowing compliance, and the technical problem that the slow-release framework function is difficult to maintain under the condition that the weight of a high-drug-loading-capacity compound preparation is greatly reduced is successfully solved.

The present invention relates to a film coated tablet comprising empagliflozin and metformin hydrochloride, wherein comprising at least one binder which is hydroxypropyl methyl cellulose or hydroxypropyl cellulose or mixtures thereof, the tablet provides pharmacotechnical properties and the desired dissolution profile. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient method of preparing the tablet.

A single-layer tablet comprising linagliptin, or a pharmaceutically acceptable salt thereof, metformin hydrochloride, a diluent, a glidant and a lubricant, wherein the tablet is produced by direct compression.

The application provides a sitagliptin and metformin hydrochloride sustained-release pharmaceutical composition and a preparation method and application thereof, and relates to the technical field of sustained-release preparations. The pharmaceutical composition comprises a sustained-release tablet core and a quick-release coating layer; the sustained-release tablet core comprises active ingredients metformin hydrochloride and a sustained-release matrix material hydroxypropyl methyl cellulose, and the sustained-release tablet core does not contain microcrystalline cellulose; the quick-release coating layer comprises active ingredients sitagliptin phosphate; the weight ratio of metformin hydrochloride to hydroxypropyl methyl cellulose in the sustained-release tablet core is 50:(24-27). The composition realizes double-phase release of drugs by using a double-layer structure; by removing the microcrystalline cellulose and limiting the specific ratio of active ingredients to the matrix material, the forming property of the preparation and the ideal dissolution behavior are ensured while the tablet weight is significantly reduced to improve the swallowing compliance, and the technical problem that a high drug loading compound preparation is difficult to maintain the function of the sustained-release matrix under a large amount of weight reduction is successfully solved.

The present invention belongs to the technical field of hypoglycemic drugs, and specifically relates to a hypoglycemic pharmaceutical composition, a pharmaceutical preparation and a preparation method thereof. The hypoglycemic pharmaceutical composition and the pharmaceutical preparation comprise metformin hydrochloride, as well as a mixed granule of bitter melon extract and microcrystalline cellulose. The preparation method of the hypoglycemic pharmaceutical preparation comprises the following steps: Step 1, preparing a mixed granule of bitter melon extract and microcrystalline cellulose; Step 2, treating metformin hydrochloride and excipients for standby; Step 3, premixing the raw and auxiliary materials in Step 1 and Step 2; Step 4, sieving and sizing the powder premixed in Step 3; Step 5, adding a lubricant to the sized powder in Step 4 for total mixing; Step 6, tabletting and packaging the granules after total mixing in Step 5. By using the pharmaceutical composition or the pharmaceutical preparation of the present invention, it is possible to prevent and treat diabetes while reducing the incidence of gastrointestinal reactions caused by metformin hydrochloride.

The present disclosure provides a preparation method for metformin hydrochloride. The preparation method includes: microwave heating raw materials containing dicyandiamide and dimethylamine hydrochloride, and reacting the two at 100° C. to 160° C. to obtain a product system containing metformin hydrochloride. Microwave heating is adopted to heat the dicyandiamide and the dimethylamine hydrochloride. Compared with a conventional heating mode that requires heat to be gradually transferred from the outside to the inside, microwave heating can directly heat each part inside the reactant, which can make the internal temperature of the reactant more uniform, thereby reducing the generation of impurities.

The invention relates to a dapagliflozin and metformin sustained-release tablet, the sustained-release tablet comprises a metformin hydrochloride sustained-release tablet core, the sustained-release tablet core is sequentially coated with an isolation coating layer and a dapagliflozin quick-release coating layer, the dapagliflozin quick-release coating layer comprises dapagliflozin or a pharmaceutically acceptable salt thereof and a first adhesive, and the metformin hydrochloride sustained-release tablet core comprises a metformin hydrochloride sustained-release tablet core, a metformin hydrochloride sustained-release tablet core, a metformin hydrochloride sustained-release tablet core and a metformin hydrochloride sustained-release tablet core, the first binder is not hydroxypropyl methyl cellulose. According to the dapagliflozin sustained-release tablet and the preparation method thereof, by optimizing the types of adhesives in a dapagliflozin quick-release coating layer, the sustained-release tablet with the in-vitro release degree consistent with that of dapagliflozin in an original commercially-available preparation # imgabs0 # imgabs1 # is obtained. In addition, the dapagliflozin and metformin sustained-release tablet disclosed by the invention is simple in preparation process and easy for large-scale production.

The invention discloses a terbium-doped benzene polycarboxylic acid-metformin HOF material and application thereof in detection of an explosive precursor sodium hypochlorite, and belongs to the technical field of fluorescent probes and fluorescence detection. The terbium-doped benzene polycarboxylic acid-metformin HOF material is formed by coordination compounding of an HOF matrix and rare earth metal ions Tb < 3 + >, and the HOF matrix is formed by self-assembly of benzene polycarboxylic acid compounds and metformin hydrochloride through intermolecular hydrogen bonds. The material can generate high-selectivity fluorescence quenching response to sodium hypochlorite (NaClO) through characteristic fluorescence emission (5D4-7F5 transition) of Tb < 3 + > at 545nm, is low in detection limit and wide in linear range, and can be used for realizing rapid and high-sensitivity detection of low-concentration NaClO. And the method has great significance in blocking the synthesis of explosives based on NaClO.

Extended-release formulation of metformin and berberine for long-lasting antidiabetic effects, comprehensive a) Metformin HCl in a quantity of 750 mg, b) Berberine HCl in an amount of 290 mg, c) Hydroxypropylmethylcellulose as the release-controlling polymer in an amount of 160 mg, d) Polyvinylpyrrolidone as a binder in an amount of 28 mg, e) microcrystalline cellulose as a filler in an amount of 170 mg, f) Magnesium stearate as a lubricant in an amount of 8 mg, g) colloidal silicon dioxide as a lubricant in an amount of 4 mg, h) Sodium stearyl fumarate as a lubricant in an amount of 6 mg, i) Talc as an anti-adhesive in an amount of 6 mg, wherein the composition is formulated for prolonged-release drug delivery to provide prolonged therapeutic effects in the treatment of diabetes mellitus.

The invention discloses a Chinese herbaceous peony 'Salaa' cut flower fresh-keeping method. The Chinese herbaceous peony 'Salaa' cut flower fresh-keeping method comprises the step of inserting Chinese herbaceous peony 'Salaa' cut flowers into fresh-keeping liquid containing metformin hydrochloride and acarbose. The metformin hydrochloride and the acarbose are especially added into the Chinese herbaceous peony cut flower fresh-keeping liquid, so that the effect of synergistically adjusting flowering genes of Chinese herbaceous peony can be achieved, the flowering phase of Chinese herbaceous peony, especially 'Saxa' fresh cut flowers, is practically and effectively prolonged, and the flower diameter, the flower height, the fresh weight, the flower fragrance and the like are improved.

The invention provides a novel metformin hydrochloride enteric-coated preparation, which is an oral dosage form prepared from a therapeutically effective amount of biguanide compound and pharmaceutically acceptable auxiliary materials, and is characterized in that the dissolution rate of metformin hydrochloride in a medium with the pH value of 4.5 within 120 minutes is not higher than 15%; and the dissolution rate of metformin hydrochloride in a medium with the pH value of 6.8 within 20 minutes is not lower than 85%, preferably, the dissolution rate in a medium with the pH value of 4.5 within 120 minutes is not higher than 7.5%, and the dissolution rate in a medium with the pH value of 6.8 within 15 minutes is not lower than 85%. The metformin hydrochloride enteric-coated preparation meeting the technical requirements of medicine dissolution improves the gastrointestinal tract tolerance of metformin hydrochloride and reduces adverse reactions caused by medicines under the condition that the hypoglycemic curative effect is not reduced or even improved, can be taken before meals, and can also be taken after meals or during meals, so that the metformin hydrochloride enteric-coated preparation is suitable for clinical application. The medicine taking compliance of a patient is improved.

The present invention relates to a stable, fixed-dose combination formulation comprising sitagliptin or pharmaceutically acceptable salts or derivatives thereof in combination with metformin hydrochloride and one or more pharmaceutically acceptable excipient manufactured by wet granulation method in monolayer dosage form.

A metformin hydrochloride enteric-coated tablet, which consists of a tablet core containing a therapeutically effective amount of metformin hydrochloride and an enteric coating layer wrapping the tablet core, and has a metformin hydrochloride dissolution of not higher than 15% within 2 hours in a pH 4.5 medium and a metformin hydrochloride dissolution of not less than 85% within 20 minutes in a pH 6.8 medium. The metformin hydrochloride enteric-coated tablet, which meets specific drug release technical requirements, is obtained by means of selecting the disintegration time limit of the tablet core, the dissolution point of the enteric coating material and the weight gain of the coating. Compared with common preparations of metformin hydrochloride (such as glucophage) and enteric-coated tablets having other release characteristics, the metformin hydrochloride enteric-coated tablet improves the tolerance and compliance of metformin hydrochloride without reducing the hypoglycemic efficacy.

Disclosed herein is an invention that refers to hydrochloride metformin complexes with transition metals and group P elements, such as cobalt (II), nickel (II), copper (II), zinc (III), iron (II), bismuth (III) and their preparation method. Additionally, the present invention offers crystalline forms of the metformin-cobalt (II) complex, metformin-nickel complex and metformin-copper complex as well as methods for therapeutic use in patient treatment and their preparation method.

The application provides a method for simultaneously determining the content of dapagliflozin and metformin, which adopts a reverse-phase high performance liquid chromatography method to separate and determine the content of dapagliflozin and metformin in dapagliflozin and metformin sustained-release tablets. The method has good separation degree, solvent does not interfere with detection, and good method specificity. The detection method is simple, rapid, accurate, high in sensitivity, good in repeatability and accuracy, can quickly and accurately perform qualitative and quantitative analysis on the content of dapagliflozin and metformin hydrochloride in dapagliflozin and metformin sustained-release tablets, and ensures the controllability of the quality of the product.

The present application relates to the technical field of medicine preparation, and discloses a macrophage membrane liposome packaged metformin drug delivery system, a preparation method thereof and application in tumor treatment, which comprises a ZIF-8 carrier carrying a medical active substance of metformin hydrochloride, wherein the metformin hydrochloride is encapsulated in ZIF-8 nanoparticles, and the outer layer is packaged with tumor-related macrophage membrane liposomes; in application examples, it is found through in-vitro experiments that the killing effect of the system on human osteosarcoma cell lines is strong, the system can more effectively kill tumor cells and induce immunogenic death; compared with free metformin hydrochloride monomer drugs, the aforementioned delivery system has a more obvious inhibitory effect on tumor cells and can more effectively induce immunogenic death.

The invention discloses a metformin hydrochloride rapid-release capsule and a preparation method thereof, the preparation method comprising the following steps: ① putting the metformin hydrochloride raw material and the binder into a wet mixing granulator according to the prescription amount ratio, wet mixing and granulation; ② vacuum drying the wet granules obtained in step ①; ③ granulation; ④ adding the prescribed amount of lubricant and mixing; ⑤ capsule filling; the binder is selected from hydroxypropyl methylcellulose and / or polyvinyl pyrrolidone and the amount of the binder does not exceed 0.2% of the weight of the metformin hydrochloride raw material; the wet mixing granulation time in step ① is 1 to 5 minutes, and the vacuum drying time in step ② is 3 to 4 hours. The present invention can obtain a metformin hydrochloride rapid-release capsule with uniform particles, good fluidity, small loading difference and less impurity content by optimizing the formulation formula and process parameters, and the metformin hydrochloride rapid-release capsule has high bioavailability, fast disintegration in the gastrointestinal tract and good absorption.

This invention provides a method for preparing a metformin compound hypoglycemic oral solution, relating to the pharmaceutical field, comprising: step S1, pretreatment of traditional Chinese medicine components; step S2, enzymatic hydrolysis of the first group of traditional Chinese medicine components; step S3, supercritical extraction; step S4, preparation of mixed traditional Chinese medicines; step S5, preparation of inclusion complex; step S6, compound formulation; and step S7, post-processing. This method synergistically combines extracts from seven traditional Chinese medicines—bitter melon, phellodendron bark, astragalus root, kudzu root, rehmannia root, ginseng, and privet fruit—with metformin hydrochloride to form a metformin compound hypoglycemic oral solution, balancing the synergy, safety, and stability of traditional Chinese and Western medicines, thereby improving hypoglycemic effects while reducing the incidence of gastrointestinal adverse reactions to metformin.

The invention discloses a dapagliflozin and metformin sustained release tablet and a preparation method thereof. The dapagliflozin sustained-release tablet is prepared from the following raw materials in percentage by mass: 1.5 to 5.0 percent of dapagliflozin, 70.0 to 80.0 percent of metformin hydrochloride, 20 to 70 percent of filling agent, 3 to 8 percent of disintegrating agent, 2.0 to 10.0 percent of sustained-release material, 0.5 to 5.0 percent of adhesive solution, 20.0 to 30.0 percent of wetting agent, 0.5 to 2 percent of lubricating agent and 0.2 to 1.5 percent of flow aid. By adopting a wet granulation process, the dissolution rate of dapagliflozin and the release rate of metformin hydrochloride in the dapagliflozin and metformin hydrochloride sustained-release tablet can be increased, the content uniformity is good, the release is complete, and the stability and effectiveness of the product and the use safety of a patient are greatly improved.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to a sustained release preparation containing empagliflozin and metformin hydrochloride and a preparation method of the sustained release preparation. The method comprises the following steps: (1) preparing a sustained-release bulk drug, a sustained-release skeleton auxiliary material A, a sustained-release skeleton auxiliary material B, a lubricant and purified water into a tablet core; (2) preparing a coating spacer fluid from a film-forming agent, a thickening agent, a plasticizer, an opacifying agent and purified water; (3) preparing a coating liquid medicine from the quick-release bulk drug, a film-forming agent, a thickening agent, a plasticizer, an opacifying agent and purified water; (4) preparing a sealing solution from a film-forming agent, a plasticizer, an opacifying agent, a color lake and purified water; and (5) sequentially treating the tablet core with a spacer fluid, a coating liquid medicine and a sealing fluid to prepare the empagliflozin and metformin hydrochloride sustained release tablet. Under the condition of ensuring similar dissolution curves, polyoxyethylene is replaced, and the risk of high-temperature burst release of a large amount of metformin hydrochloride is avoided; and the coating process and the process flow are simplified, and the material consumption is reduced.